David A. Ricks
Also at Eli Lilly and Co
About
David A. Ricks serves as the Chair, President, and Chief Executive Officer of Eli Lilly and Company, bringing a wealth of experience from a 28-year career at the firm. At 57 years old as of 2024 , his leadership reflects decades of service and strategic guidance across various divisions of the company.
Throughout his distinguished career, he has held key roles including positions in marketing, sales, and international operations, progressing from significant leadership roles such as President of Lilly USA and Senior Vice President & President of Lilly Bio-Medicines to ultimately leading the company as CEO in 2017.
In addition to his executive roles at LLY, he contributes to the broader industry by serving on the board of directors for Adobe Inc. and participating in several industry organizations such as the Pharmaceutical Research and Manufacturers of America and the International Federation of Pharmaceutical Manufacturers & Associations.
$LLY Performance Under David A. Ricks
Past Roles
| Organization | Role | Date Range | Details [N/A] |
|---|---|---|---|
| Eli Lilly and Company | Senior Vice President and President, Lilly Bio-Medicines | 2012–2016 | N/A |
| Eli Lilly and Company | President, Lilly USA | 2009–2012 | N/A |
| Eli Lilly and Company | President and General Manager, Lilly China | 1996–2009 | N/A |
| Eli Lilly and Company | General Manager, Lilly Canada | 1996–2009 | N/A |
External Roles
| Organization | Role | Date Range | Details [N/A] |
|---|---|---|---|
| Adobe Inc. | Director | N/A | N/A |
Fixed Compensation
| Component Name | Amount | Payment Schedule | Additional Details |
|---|---|---|---|
| Salary | $1,621,154 | Annually (2023) | Fixed base salary |
| Nonqualified Savings Plan Contributions | $77,469 | Annually (2023) | Employer contribution |
| 401(k) Contributions | $19,800 | Annually (2023) | Derived from total matching contributions of $97,269 minus Nonqualified Savings Plan Contributions |
| Personal Use of Corporate Aircraft | $65,804 | Annually (2023) | Incremental cost for personal use |
| HSR Filing Fee Reimbursement | $100,000 | Annually (2023) | Reimbursed fee processed as imputed income for tax withholding |
Performance Compensation
Non-Equity Incentive Plan Compensation (Bonus Plan)
| Metric [Weight] (%) | Target/Threshold Detail | Actual Result/Multiplier | Payout Amount (USD) |
|---|---|---|---|
| Revenue [25%] | Not explicitly provided | – | – |
| EPS [50%] | Target: 2.0% annual growth (cumulative goal not detailed) | – | – |
| Pipeline Progress [25%] | Targets include: 2 new drug first approvals; 9 other approvals (among other metrics) | Pipeline multiple: 1.86 | – |
| Overall Bonus | Payout Multiple: 181% of target | – | $4,401,433 |
| Evaluation Period: Annual 2023; no vesting as award is cash-based |
2023-2025 Performance Awards (EPS-Based)
| Metric [Detail] | Value | Notes |
|---|---|---|
| Grant Date | Feb 10, 2023 | – |
| Grant Date Fair Value (USD) | $6,327,750 | Determined at grant date |
| Performance Metric | EPS Growth | Assessed via cumulative 2-year EPS performance |
| Threshold Shares | 7,983 | 0% payout if cumulative EPS ≤ $16.12 |
| Target Shares | 15,966 | 100% payout if cumulative EPS = $18.21 |
| Maximum Shares | 31,932 | 200% payout if cumulative EPS ≥ $21.57 |
| Vesting Schedule | February 2026 | Contingent upon meeting employment requirements |
2023-2025 Shareholder Value Awards (SVA)
| Metric [Detail] | Value | Notes |
|---|---|---|
| Grant Date | Feb 10, 2023 | – |
| Grant Date Fair Value (USD) | $6,256,250 | – |
| Weighted-Average Fair Value (USD) | $349.63 | Derived via Monte Carlo simulation |
| Performance Metric | Final Stock Price | Based on 3-year stock performance |
| Payout Threshold | Final Price < $347.53 | Results in 0% payout |
| Payout Target | Final Price = $441.12 | 100% payout |
| Payout Maximum | Final Price > $584.73 | 200% payout |
| Target Shares | 19,512 | – |
| Maximum Shares | 39,024 | 200% of target |
| Vesting Schedule | December 31, 2025 | Subject to a one-year post-vesting holding requirement |
2023-2025 Relative Value Awards (RVA)
| Metric [Detail] | Value | Notes |
|---|---|---|
| Grant Date | Feb 10, 2023 | – |
| Grant Date Fair Value (USD) | $6,256,250 | – |
| Performance Metric | Relative TSR vs. peer group | Assesses total shareholder return relative to peers |
| Payout Threshold | ≤ -24.0 pp difference | Yields 0% payout |
| Payout Target | At Peer Median TSR | Yields 100% payout |
| Payout Maximum | ≥ +30.0 pp difference | Yields 200% payout |
| Target Shares | 15,721 | – |
| Maximum Shares | 31,442 | 200% of target |
| Vesting Schedule | December 31, 2025 | Contingent on continued employment |